Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

Back to Myelodysplastic/myeloproliferative Disease

Myelodysplastic/myeloproliferative Disease — NIH Grants & Funding

Active and recent NIH-funded research on Myelodysplastic/myeloproliferative Disease. Data from NIH RePORTER, last 36 months.

MONDO:0020077

Looking for specific grants? The Recent Research tab lets you search and filter by topic.

Funding Landscape

Myelodysplastic/myeloproliferative Disease has active NIH research funding with 7 funded grants totaling $6.0M.

7funded grants from NIH

Portfolio: $1.8MCumulative: $6.0M4 active3 completed7 PIs6 institutions

By Research Theme

Basic Science

Translational

Epi / Nat. History

Funding by Fiscal Year

NIH fiscal year (Oct–Sep)

$786K

FY22

$1.7M

FY23

$1.5M

FY24

$1.2M

FY25

$752K

FY26

By Funding Mechanism

R01

K08

K99

Funding Gap Analysis

Cross-referencing NIH grants against published research and clinical trials to identify funding-evidence gaps for Myelodysplastic/myeloproliferative Disease. Strongest funded area: Basic Science. Largest gap: Basic Science.

Basic ScienceFunded, Few Publications

5 funded grants in Basic Science but only 0 related publications found for myelodysplastic/myeloproliferative disease. This may indicate early-stage research that hasn't yet produced published results.

Adjacent Research(3 grants)

These grants mention Myelodysplastic/myeloproliferative Disease as part of broader research but are not primarily focused on this disease. They are not included in the funding totals above.

Other(3)

OtherP01Active

Aging-related hematopoietic stem cell intrinsic and microenvironmental signals in AML transformation

KOUSTENI, STAVROULA·COLUMBIA UNIVERSITY HEALTH SCIENCES·NEW YORK, NY

$2,747,089 (FY2025)

NIH RePORTER

OtherR01Active

The Role of miR-142 in the Transformation of Clonal Hematopoietic Disorders into AML

MARCUCCI, GUIDO et al.·BECKMAN RESEARCH INSTITUTE/CITY OF HOPE·DUARTE, CA

$542,890 (FY2026)

NIH RePORTER

OtherR01Completed

Hyperglycemia mediated myeloproliferative disease

Kapur, Reuben·INDIANA UNIVERSITY INDIANAPOLIS·INDIANAPOLIS, IN

$582,811 (FY2022)

NIH RePORTER

NIH Grants & Funding for Myelodysplastic/myeloproliferative Disease | Kisho | Kisho

Kisho

Myelodysplastic/myeloproliferative Disease — NIH Grants & Funding

Funding Landscape

By Research Theme

Funding by Fiscal Year

By Funding Mechanism

Funding Gap Analysis

Adjacent Research(3 grants)

Other(3)

Aging-related hematopoietic stem cell intrinsic and microenvironmental signals in AML transformation

The Role of miR-142 in the Transformation of Clonal Hematopoietic Disorders into AML

Hyperglycemia mediated myeloproliferative disease

Top Funded Institutions

Top Principal Investigators